R&D funding selected diseases globally 2020-2022

The statistic shows the distribution of total global funding on research and development for selected diseases from 2020 to 2022. In 2022, the share of funding on research and development on HIV and AIDS amounted to 34 percent.

Distribution of total global funding on research and development for selected diseases from 2020 to 2022

Characteristic	2020	2021	2022
HIV/AIDS	35%	35%	34%
Tuberculosis	17%	17%	18%
Malaria	16%	15%	15%
Diarrhoeal diseases	3.8%	3.3%	4%
Kinetoplastida	3.7%	3.2%	3.2%
Worms and flukes	1.9%	2.1%	2.6%
Dengue	1.9%	1.9%	2.1%
Salmonella infections	1.9%	1.7%	2%
Bacterial pneunomia/meningitis	1.7%	1.5%	1.2%
Hepatitis B	0.5%	0.4%	0.8%
Snakebite envenoming	0.4%	0.4%	0.5%
Hepatitis C	0.4%	0.4%	0.4%
Leprosy	0.2%	0.2%	0.3%
Cryptococcal meningitis	0.2%	0.3%	0.2%
Histoplasmosis	0.1%	0.1%	0.1%
Rheumatic fever	0.4%	0.2%	0.1%
Scabies	0.1%	0.1%	0.1%
Leptospirosis	0.1%	0.1%	0.1%
Buruli ulcer	0.1%	0.1%	0.1%
Mycetoma	0.1%	0.1%	0.1%
Trachoma	0.1%	0.1%	0.1%
Platform technologies	3.3%	3.5%	4.9%
Multi-disease vector control products	1.6%	1.8%	1.6%
Core funding of a multi-disease R&D organisation	8.6%	9.1%	6.3%
Other R&D	1.3%	1.7%	1.9%

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

January 2024

More information

Region

Worldwide

Survey time period

2020 to 2022

Supplementary notes

This statistic was assembled from several editions of the G-Finder report.
Please note that some of the diseases listed above are actually groups of diseases, such as the diarrhoeal illnesses and helminth infections. This reflects common practice and also the shared nature of research in some areas. For example Streptococcus pneumoniae R&D is often targeted at both pneumonia and meningitis.
No value means no data was available for the given year.
Sum may not add up to 100 percent due to rounding.

Citation formats